Company Overview and News

1
5 Jefferies Energy Franchise Picks to Buy for the Rest of 2018

2018-07-16 247wallst
Despite the efforts of OPEC and Russia, and the prodding of President Trump, oil prices continue to hover above the $70 level, with West Texas Intermediate closing Friday at $71.01 a barrel and Brent North Sea Crude at $75.30. While oil traded down Monday morning, levels are still higher than anticipated when we started 2018. Production levels remain steady in the United States, but reserves are not being replenished as demand has increased.
CVX FANG

17
Energen: A Bit About The Potential Sale

2018-07-11 seekingalpha
Energen will likely face additional pressure to complete the highly anticipated strategic review and discuss the company’s takeout potential.
APL RSPP XOM APL.PRE EGN PXD TRI CXO IEP FANG

1
Is This Energy Stock About To Pop?

2018-07-07 oilprice
As oil has recovered from its epic fall from above $100 to below $30 in 2014/15, many oil related stocks have also regained lost ground. The recovery in stocks, however has been far from even. Some, like Diamondback Energy (FANG) recovered to hit record highs, but others have still yet to recover at all. Transocean (RIG) is in that second group. That is for good reason, but it does leave plenty of room for a big jump, and a strong case can be made right now that one is coming.
FANG

12
Zacks Value Trader Highlights: Chevron, Bonanza Creek, Diamondback, Helmerich & Payne and CARBO

2018-07-05 zacks
Chicago, IL –July 5, 2018 – Zacks Value Trader is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
CRR 6755 HP CVX FGELF STX BCEI SMCI FANG

1
Your Ultimate Guide to Investing in Energy Stocks

2018-07-03 zacks
Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio service, shares some of her top value investing tips and stock picks.
CRR HP CVX BCEI FANG

1
Top Analyst Stays Positive on the Permian Basin: 5 Stocks to Buy

2018-07-03 247wallst
Once it was the hottest oil and natural gas production region in the United States, and the top companies focused on the Permian Basin in West Texas and New Mexico performed well. Recently though, the ability to transport production has been hampered by pipeline capacity issues. As a result, some of the top Permian stocks have been hit hard, and investors are literally being offered some of the best entry points in years.
XEC FANG

36
U.S. Shale: NAV Analysis Of Permian Basin - Midland Basin E&Ps - 2018 Q1 Update

2018-07-01 seekingalpha
Energen is somewhat overvalued on a DCF basis and about fairly valued on a NAV basis.
CDEV CPE SM PXD PE CXO ESTE AREX RSPP LPI EGN FANG

2
Why You Shouldn't Bet Against Diamondback Energy (FANG) Stock

2018-06-29 zacks
One stock that might be an intriguing choice for investors right now is Diamondback Energy, Inc. (FANG - Free Report) . This is because this security in the Oil and Gas - Exploration and Production - United States space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board.
GM.WS.A GM.WS.B GM.WS.C GM GM.WSB PII FANG

2
FANG / Diamondback Energy, Inc. DIAMONDBACK S-4

2018-06-28 sec.gov
Document As filed with the Securities and Exchange Commission on June 27, 2018 Registration No. 333-
FANG

0
FANG / Diamondback Energy, Inc. DIAMONDBACK S-4

2018-06-28 sec.gov
Document As filed with the Securities and Exchange Commission on June 27, 2018 Registration No. 333-
FANG

0
FANG / Diamondback Energy, Inc. DIAMONDBACK S-4

2018-06-28 sec.gov
Document As filed with the Securities and Exchange Commission on June 27, 2018 Registration No. 333-
FANG

24
Apache: The Most Undervalued Permian Producer?

2018-06-28 seekingalpha
Apache is being unfairly punished by the market as a result of its plans to commit capital outside of cash flow to developing its Alpine High assets.
APA FANG

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 25278X109